Posted On: August 23, 2011

More Warnings for Levaquin - May exacerbate muscle weakness in patients with Myasthenia Gravis

Last December, Ortho McNeil-Janssen Pharmacetuicals added new labeling to its blockbuster antibiotic Levaquin. This updated black box warning, states that "Fluoroquinolones, including Levaquin, may exacerbate muscle weakness in persons with myasthenia gravis," a neuromuscular disorder. Levaquin and other fluoroquinolones have neuromuscular blocking activity and have been linked to serious adverse events in patients with myasthenia gravis, including ventilatory support and deaths. This warning is in addition to the July 2008 Black Box warning concerning the increased risk of tendonitis and tendon rupture.

Continue reading " More Warnings for Levaquin - May exacerbate muscle weakness in patients with Myasthenia Gravis " »

Bookmark and Share